Regorafenib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cancer of the Bile Duct

Conditions

Cancer of the Bile Duct

Trial Timeline

Jun 5, 2014 → Sep 20, 2021

NCT ID

NCT02115542

About Regorafenib

Regorafenib is a phase 2 stage product being developed by Bayer for Cancer of the Bile Duct. The current trial status is completed. This product is registered under clinical trial identifier NCT02115542. Target conditions include Cancer of the Bile Duct.

What happened to similar drugs?

20 of 20 similar drugs in Cancer of the Bile Duct were approved

Approved (20) Terminated (4) Active (0)

✅arzoxifeneEli LillyApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved

✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06902246	Phase 2	Recruiting	Jan 5, 2026	Jan 5, 2031	Unresectable Hepatocellular Carcinoma
NCT06087263	Phase 2	Active	Jun 18, 2024	Jul 1, 2034	Gastrointestinal Stromal Tumors
NCT05134532	Phase 2	UNKNOWN	Dec 24, 2021	Oct 30, 2024	Hepatocellular Carcinoma
NCT03627728	Phase 2	Completed	Jun 13, 2018	Oct 31, 2024	Gastric Cancer
NCT03042689	Phase 1	Completed	Apr 17, 2017	Feb 27, 2023	Acute Myeloid Leukemia
NCT02835924	Phase 2	Completed	Jul 1, 2016	Sep 1, 2019	Metastatic Colorectal Cancer
NCT02581059	Phase 2	Terminated	Apr 1, 2016	Jun 22, 2018	Colorectal Cancer
NCT02657551	Phase 2	Active	Jan 1, 2016	Dec 1, 2025	Thyroid Cancer
NCT02638766	Phase 2	Completed	Nov 1, 2015	Aug 31, 2021	Gastrointestinal Stromal Tumors
NCT02459119	Phase 2	Completed	May 1, 2015	Apr 1, 2020	Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
NCT02425683	Phase 2	Terminated	Mar 26, 2015	Sep 21, 2017	Colorectal Neoplasms
NCT02466009	Phase 2	Completed	Mar 1, 2015	Mar 9, 2022	Metastatic Colorectal Cancer
NCT02278783	Phase 2	Terminated	Mar 1, 2015	Jan 1, 2017	Ovarian Cancer
NCT02402036	Phase 2	Terminated	Feb 1, 2015	Nov 1, 2017	Colon Cancer
NCT03010722	Pre-clinical	Completed	Jan 1, 2015	Jul 1, 2017	Metastatic Colorectal Cancer
NCT02048722	Phase 2	Completed	Jun 13, 2014	Oct 12, 2021	Adult Angiosarcoma
NCT02080260	Phase 2	Completed	Jun 6, 2014	Jun 28, 2017	Pancreatic Cancer
NCT02115542	Phase 2	Completed	Jun 5, 2014	Sep 20, 2021	Cancer of the Bile Duct
NCT02175654	Phase 2	Terminated	Jun 1, 2014	Feb 1, 2016	Colorectal Neoplasms
NCT02098538	Phase 2	Completed	Mar 1, 2014	Nov 7, 2024	Adenoid Cystic Carcinoma

Competing Products

20 competing products in Cancer of the Bile Duct

See all competitors

Product	Company	Stage	Hype Score
mFOLFOX regimen + Mitazalimab	Alligator Bioscience AB	Phase 2/3	35
Intratumoral Mitazalimab + Intratumoral Nivolumab	Alligator Bioscience AB	Phase 1	26
mRNA-2416	Moderna	Phase 2	0
Doxorubicin Hydrochloride Liposome Injection	Dr. Reddy's Laboratories	Phase 1	26
E7389	Eisai	Phase 1	29
Veliparib	AbbVie	Phase 2	27
AK-105	Akeso	Phase 1	29
XL820	Exelixis	Phase 1	26
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	31
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	30
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	35
pemetrexed	Eli Lilly	Phase 2	27
LY3300054 + Prexasertib	Eli Lilly	Phase 1	29
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	18
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	35